Targeting histone demethylases as a potential cancer therapy (Review)

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021. View Article : Google Scholar : PubMed/NCBI

Kruger S, Ilmer M, Kobold S, Cadilha BL, Endres S, Ormanns S, Schuebbe G, Renz BW, D'Haese JG, Schloesser H, et al: Advances in cancer immunotherapy 2019-latest trends. J Exp Clin Cancer Res. 38:2682019. View Article : Google Scholar : PubMed/NCBI

Thompson JA, Schneider BJ, Brahmer J, Achufusi A, Armand P, Berkenstock MK, Bhatia S, Budde LE, Chokshi S, Davies M, et al: Management of immunotherapy-related toxicities, version 1.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 20:387–405. 2022. View Article : Google Scholar : PubMed/NCBI

Michalak EM, Burr ML, Bannister AJ and Dawson MA: The roles of DNA, RNA and histone methylation in ageing and cancer. Nat Rev Mol Cell Biol. 20:573–589. 2019. View Article : Google Scholar : PubMed/NCBI

Dawson MA and Kouzarides T: Cancer epigenetics: From mechanism to therapy. Cell. 150:12–27. 2012. View Article : Google Scholar : PubMed/NCBI

Tachibana M, Sugimoto K, Nozaki M, Ueda J, Ohta T, Ohki M, Fukuda M, Takeda N, Niida H, Kato H and Shinkai Y: G9a histone methyltransferase plays a dominant role in euchromatic histone H3 lysine 9 methylation and is essential for early embryogenesis. Genes Dev. 16:1779–1791. 2002. View Article : Google Scholar : PubMed/NCBI

Peters AH, O'Carroll D, Scherthan H, Mechtler K, Sauer S, Schöfer C, Weipoltshammer K, Pagani M, Lachner M, Kohlmaier A, et al: Loss of the Suv39h histone methyltransferases impairs mammalian heterochromatin and genome stability. Cell. 107:323–337. 2001. View Article : Google Scholar : PubMed/NCBI

Dou Y, Milne TA, Ruthenburg AJ, Lee S, Lee JW, Verdine GL, Allis CD and Roeder RG: Regulation of MLL1 H3K4 methyltransferase activity by its core components. Nat Struct Mol Biol. 13:713–719. 2006. View Article : Google Scholar : PubMed/NCBI

Shi Y: Histone lysine demethylases: Emerging roles in development, physiology and disease. Nat Rev Genet. 8:829–833. 2007. View Article : Google Scholar : PubMed/NCBI

Soares LM, He PC, Chun Y, Suh H, Kim T and Buratowski S: Determinants of histone H3K4 methylation patterns. Mol Cell. 68:773–785.e6. 2017. View Article : Google Scholar : PubMed/NCBI

Fodor BD, Kubicek S, Yonezawa M, O'Sullivan RJ, Sengupta R, Perez-Burgos L, Opravil S, Mechtler K, Schotta G and Jenuwein T: Jmjd2b antagonizes H3K9 trimethylation at pericentric heterochromatin in mammalian cells. Genes Dev. 20:1557–1562. 2006. View Article : Google Scholar : PubMed/NCBI

Chen Z and Zhang Y: Maternal H3K27me3-dependent autosomal and X chromosome imprinting. Nat Rev Genet. 21:555–571. 2020. View Article : Google Scholar : PubMed/NCBI

Cloos PA, Christensen J, Agger K, Maiolica A, Rappsilber J, Antal T, Hansen KH and Helin K: The putative oncogene GASC1 demethylates tri- and dimethylated lysine 9 on histone H3. Nature. 442:307–311. 2006. View Article : Google Scholar : PubMed/NCBI

Klose RJ, Yamane K, Bae Y, Zhang D, Erdjument-Bromage H, Tempst P, Wong J and Zhang Y: The transcriptional repressor JHDM3A demethylates trimethyl histone H3 lysine 9 and lysine 36. Nature. 442:312–316. 2006. View Article : Google Scholar : PubMed/NCBI

Shi Y, Lan F, Matson C, Mulligan P, Whetstine JR, Cole PA, Casero RA and Shi Y: Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell. 119:941–953. 2004. View Article : Google Scholar : PubMed/NCBI

Vallianatos CN and Iwase S: Disrupted intricacy of histone H3K4 methylation in neurodevelopmental disorders. Epigenomics. 7:503–519. 2015. View Article : Google Scholar : PubMed/NCBI

Clark EA, Wu F, Chen Y, Kang P, Kaiser UB, Fang R and Shi YG: GR and LSD1/KDM1A-targeted gene activation requires selective H3K4me2 demethylation at enhancers. Cell Rep. 27:3522–3532.e3. 2019. View Article : Google Scholar : PubMed/NCBI

Tsukada Y, Fang J, Erdjument-Bromage H, Warren ME, Borchers CH, Tempst P and Zhang Y: Histone demethylation by a family of JmjC domain-containing proteins. Nature. 439:811–816. 2006. View Article : Google Scholar : PubMed/NCBI

Trojer P, Zhang J, Yonezawa M, Schmidt A, Zheng H, Jenuwein T and Reinberg D: Dynamic histone H1 isotype 4 methylation and demethylation by histone lysine methyltransferase G9a/KMT1C and the Jumonji domain-containing JMJD2/KDM4 proteins. J Biol Chem. 284:8395–8405. 2009. View Article : Google Scholar : PubMed/NCBI

Suzuki T, Ozasa H, Itoh Y, Zhan P, Sawada H, Mino K, Walport L, Ohkubo R, Kawamura A, Yonezawa M, et al: Identification of the KDM2/7 histone lysine demethylase subfamily inhibitor and its antiproliferative activity. J Med Chem. 56:7222–7231. 2013. View Article : Google Scholar : PubMed/NCBI

Berry WL and Janknecht R: KDM4/JMJD2 histone demethylases: Epigenetic regulators in cancer cells. Cancer Res. 73:2936–2942. 2013. View Article : Google Scholar : PubMed/NCBI

Turberfield AH, Kondo T, Nakayama M, Koseki Y, King HW, Koseki H and Klose RJ: KDM2 proteins constrain transcription from CpG island gene promoters independently of their histone demethylase activity. Nucleic Acids Res. 47:9005–9023. 2019. View Article : Google Scholar : PubMed/NCBI

Tian Z, Yao L, Shen Y, Guo X and Duan X: Histone H3K9 demethylase JMJD1A is a co-activator of erythropoietin expression under hypoxia. Int J Biochem Cell Biol. 109:33–39. 2019. View Article : Google Scholar : PubMed/NCBI

Sui Y, Gu R and Janknecht R: Crucial functions of the JMJD1/KDM3 epigenetic regulators in cancer. Mol Cancer Res. 19:3–13. 2021. View Article : Google Scholar : PubMed/NCBI

Wagner KW, Alam H, Dhar SS, Giri U, Li N, Wei Y, Giri D, Cascone T, Kim JH, Ye Y, et al: KDM2A promotes lung tumorigenesis by epigenetically enhancing ERK1/2 signaling. J Clin Invest. 123:5231–5246. 2013. View Article : Google Scholar : PubMed/NCBI

Hughes AL, Kelley JR and Klose RJ: Understanding the interplay between CpG island-associated gene promoters and H3K4 methylation. Biochim Biophys Acta Gene Regul Mech. 1863:1945672020. View Article : Google Scholar : PubMed/NCBI

Barski A, Cuddapah S, Cui K, Roh TY, Schones DE, Wang Z, Wei G, Chepelev I and Zhao K: High-resolution profiling of histone methylations in the human genome. Cell. 129:823–837. 2007. View Article : Google Scholar : PubMed/NCBI

Chen Y, Yang Y, Wang F, Wan K, Yamane K, Zhang Y and Lei M: Crystal structure of human histone lysine-specific demethylase 1 (LSD1). Proc Natl Acad Sci USA. 103:13956–13961. 2006. View Article : Google Scholar : PubMed/NCBI

Arifuzzaman S, Khatun MR and Khatun R: Emerging of lysine demethylases (KDMs): From pathophysiological insights to novel therapeutic opportunities. Biomed Pharmacother. 129:1103922020. View Article : Google Scholar : PubMed/NCBI

Carnesecchi J, Forcet C, Zhang L, Tribollet V, Barenton B, Boudra R, Cerutti C, Billas IM, Sérandour AA, Carroll JS, et al: ERRα induces H3K9 demethylation by LSD1 to promote cell invasion. Proc Natl Acad Sci USA. 114:3909–3914. 2017. View Article : Google Scholar : PubMed/NCBI

He Y, Zhao Y, Wang L, Bohrer LR, Pan Y, Wang L and Huang H: LSD1 promotes S-phase entry and tumorigenesis via chromatin co-occupation with E2F1 and selective H3K9 demethylation. Oncogene. 37:534–543. 2018. View Article : Google Scholar : PubMed/NCBI

Wang Y and Cao K: KDM1A promotes immunosuppression in hepatocellular carcinoma by regulating PD-L1 through demethylating MEF2D. J Immunol Res. 2021:99650992021. View Article : Google Scholar : PubMed/NCBI

Hou X, Li Q, Yang L, Yang Z, He J, Li Q and Li D: KDM1A and KDM3A promote tumor growth by upregulating cell cycle-associated genes in pancreatic cancer. Exp Biol Med (Maywood). 246:1869–1883. 2021. View Article : Google Scholar : PubMed/NCBI

Kim HS, Son BK, Kwon MJ, Kim DH and Min KW: High KDM1A expression associated with decreased CD8+ T cells reduces the breast cancer survival rate in patients with breast cancer. J Clin Med. 10:11122021. View Article : Google Scholar : PubMed/NCBI

Majello B, Gorini F, Saccà CD and Amente S: Expanding the role of the histone lysine-specific demethylase LSD1 in cancer. Cancers (Basel). 11:3242019. View Article : Google Scholar : PubMed/NCBI

Huang J, Sengupta R, Espejo AB, Lee MG, Dorsey JA, Richter M, Opravil S, Shiekhattar R, Bedford MT, Jenuwein T and Berger SL: p53 is regulated by the lysine demethylase LSD1. Nature. 449:105–108. 2007. View Article : Google Scholar : PubMed/NCBI

Cho HS, Suzuki T, Dohmae N, Hayami S, Unoki M, Yoshimatsu M, Toyokawa G, Takawa M, Chen T, Kurash JK, et al: Demethylation of RB regulator MYPT1 by histone demethylase LSD1 promotes cell cycle progression in cancer cells. Cancer Res. 71:655–660. 2011. View Article : Google Scholar : PubMed/NCBI

Saccà CD, Gorini F, Ambrosio S, Amente S, Faicchia D, Matarese G, Lania L and Majello B: Inhibition of lysine-specific demethylase LSD1 induces senescence in glioblastoma cells through a HIF-1α-dependent pathway. Biochim Biophys Acta Gene Regul Mech. 1862:535–546. 2019. View Article : Google Scholar : PubMed/NCBI

Qin Y, Vasilatos SN, Chen L, Wu H, Cao Z, Fu Y, Huang M, Vlad AM, Lu B, Oesterreich S, et al: Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and enhances antitumor efficacy of immune checkpoint blockade. Oncogene. 38:390–405. 2019. View Article : Google Scholar : PubMed/NCBI

Katz TA, Vasilatos SN, Harrington E, Oesterreich S, Davidson NE and Huang Y: Inhibition of histone demethylase, LSD2 (KDM1B), attenuates DNA methylation and increases sensitivity to DNMT inhibitor-induced apoptosis in breast cancer cells. Breast Cancer Res Treat. 146:99–108. 2014. View Article : Google Scholar : PubMed/NCBI

Cai S, Wang J, Zeng W, Cheng X, Liu L and Li W: Lysine-specific histone demethylase 1B (LSD2/KDM1B) represses p53 expression to promote proliferation and inhibit apoptosis in colorectal cancer through LSD2-mediated H3K4me2 demethylation. Aging (Albany NY). 12:14990–15001. 2020. View Article : Google Scholar : PubMed/NCBI

Cao Y, Guo C, Yin Y, Li X and Zhou L: Lysine-specific demethylase 2 contributes to the proliferation of small cell lung cancer by regulating the expression of TFPI-2. Mol Med Rep. 18:733–740. 2018.PubMed/NCBI

Kumar A, Kumari N, Sharma U, Ram S, Singh SK, Kakkar N, Kaushal K and Prasad R: Reduction in H3K4me patterns due to aberrant expression of methyltransferases and demethylases in renal cell carcinoma: Prognostic and therapeutic implications. Sci Rep. 9:81892019. View Article : Google Scholar : PubMed/NCBI

Wang Y, Sun L, Luo Y and He S: Knockdown of KDM1B inhibits cell proliferation and induces apoptosis of pancreatic cancer cells. Pathol Res Pract. 215:1054–1060. 2019. View Article : Google Scholar : PubMed/NCBI

Wang T, Chen K, Zeng X, Yang J, Wu Y, Shi X, Qin B, Zeng L, Esteban MA, Pan G and Pei D: The histone demethylases Jhdm1a/1b enhance somatic cell reprogramming in a vitamin-C-dependent manner. Cell Stem Cell. 9:575–587. 2011. View Article : Google Scholar : PubMed/NCBI

Kong Y, Zou S, Yang F, Xu X, Bu W, Jia J and Liu Z: RUNX3-mediated up-regulation of miR-29b suppresses the proliferation and migration of gastric cancer cells by targeting KDM2A. Cancer Lett. 381:138–148. 2016. View Article : Google Scholar : PubMed/NCBI

Wang F, Liang S, Liu X, Han L, Wang J and Du Q: LINC00460 modulates KDM2A to promote cell proliferation and migration by targeting miR-342-3p in gastric cancer. Onco Targets Ther. 11:6383–6394. 2018. View Article : Google Scholar : PubMed/NCBI

Ou R, Zhu L, Zhao L, Li W, Tao F, Lu Y, He Q, Li J, Ren Y and Xu Y: HPV16 E7-induced upregulation of KDM2A promotes cervical cancer progression by regulating miR-132-radixin pathway. J Cell Physiol. 234:2659–2671. 2019. View Article : Google Scholar : PubMed/NCBI

Lu DH, Yang J, Gao LK, Min J, Tang JM, Hu M, Li Y, Li ST, Chen J and Hong L: Lysine demethylase 2A promotes the progression of ovarian cancer by regulating the PI3K pathway and reversing epithelial-mesenchymal transition. Oncol Rep. 41:917–927. 2019.PubMed/NCBI

Zhao Y, Chen X, Jiang J, Wan X, Wang Y and Xu P: Epigallocatechin gallate reverses gastric cancer by regulating the long noncoding RNA LINC00511/miR-29b/KDM2A axis. Biochim Biophys Acta Mol Basis Dis. 1866:1658562020. View Article : Google Scholar : PubMed/NCBI

Xi C, Ye NY and Wang YB: LncRNA LINC01278 accelerates colorectal cancer progression via miR-134-5p/KDM2A axis. Eur Rev Med Pharmacol Sci. 24:10526–10534. 2020.PubMed/NCBI

Kottakis F, Polytarchou C, Foltopoulou P, Sanidas I, Kampranis SC and Tsichlis PN: FGF-2 regulates cell proliferation, migration, and angiogenesis through an NDY1/KDM2B-miR-101-EZH2 pathway. Mol Cell. 43:285–298. 2011. View Article : Google Scholar : PubMed/NCBI

Tzatsos A, Paskaleva P, Ferrari F, Deshpande V, Stoykova S, Contino G, Wong KK, Lan F, Trojer P, Park PJ and Bardeesy N: KDM2B promotes pancreatic cancer via polycomb-dependent and -independent transcriptional programs. J Clin Invest. 123:727–739. 2013.PubMed/NCBI

Kuang Y, Lu F, Guo J, Xu H, Wang Q, Xu C, Zeng L and Yi S: Histone demethylase KDM2B upregulates histone methyltransferase EZH2 expression and contributes to the progression of ovarian cancer in vitro and in vivo. Onco Targets Ther. 10:3131–3144. 2017. View Article : Google Scholar : PubMed/NCBI

Sanches JGP, Song B, Zhang Q, Cui X, Yabasin IB, Ntim M, Li X, He J, Zhang Y, Mao J, et al: The role of KDM2B and EZH2 in regulating the stemness in colorectal cancer through the PI3K/AKT pathway. Front Oncol. 11:6372982021. View Article : Google Scholar : PubMed/NCBI

Dhar SS, Alam H, Li N, Wagner KW, Chung J, Ahn YW and Lee MG: Transcriptional repression of histone deacetylase 3 by the histone demethylase KDM2A is coupled to tumorigenicity of lung cancer cells. J Biol Chem. 289:7483–7496. 2014. View Article : Google Scholar : PubMed/NCBI

Chen JY, Li CF, Chu PY, Lai YS, Chen CH, Jiang SS, Hou MF and Hung WC: Lysine demethylase 2A promotes stemness and angiogenesis of breast cancer by upregulating Jagged1. Oncotarget. 7:27689–27710. 2016. View Article : Google Scholar : PubMed/NCBI

Chen JY, Li CF, Lai YS and Hung WC: Lysine demethylase 2A expression in cancer-associated fibroblasts promotes breast tumour growth. Br J Cancer. 124:484–493. 2021. View Article : Google Scholar : PubMed/NCBI

Quan M, Chen Z, Jiao F, Xiao X, Xia Q, Chen J, Chao Q, Li Y, Gao Y, Yang H, et al: Lysine demethylase 2 (KDM2B) regulates hippo pathway via MOB1 to promote pancreatic ductal adenocarcinoma (PDAC) progression. J Exp Clin Cancer Res. 39:132020. View Article : Google Scholar : PubMed/NCBI

Wanna-Udom S, Terashima M, Suphakhong K, Ishimura A, Takino T and Suzuki T: KDM2B is involved in the epigenetic regulation of TGF-β-induced epithelial-mesenchymal transition in lung and pancreatic cancer cell lines. J Biol Chem. 296:1002132021. View Article : Google Scholar : PubMed/NCBI

van den Boom V, Maat H, Geugien M, Rodríguez López A, Sotoca AM, Jaques J, Brouwers-Vos AZ, Fusetti F, Groen RW, Yuan H, et al: Non-canonical PRC1.1 targets active genes independent of H3K27me3 and is essential for leukemogenesis. Cell Rep. 14:332–346. 2016. View Article : Google Scholar : PubMed/NCBI

Galbiati A, Penzo M, Bacalini MG, Onofrillo C, Guerrieri AN, Garagnani P, Franceschi C, Treré D and Montanaro L: Epigenetic up-regulation of ribosome biogenesis and more aggressive phenotype triggered by the lack of the histone demethylase JHDM1B in mammary epithelial cells. Oncotarget. 8:37091–37103. 2017. View Article : Google Scholar : PubMed/NCBI

Yoo J, Jeon YH, Cho HY, Lee SW, Kim GW, Lee DH and Kwon SH: Advances in histone demethylase KDM3A as a cancer therapeutic target. Cancers (Basel). 12:10982020. View Article : Google Scholar : PubMed/NCBI

Yamane K, Toumazou C, Tsukada Y, Erdjument-Bromage H, Tempst P, Wong J and Zhang Y: JHDM2A, a JmjC-containing H3K9 demethylase, facilitates transcription activation by androgen receptor. Cell. 125:483–495. 2006. View Article : Google Scholar : PubMed/NCBI

Chen M, Zhu N, Liu X, Laurent B, Tang Z, Eng R, Shi Y, Armstrong SA and Roeder RG: JMJD1C is required for the survival of acute myeloid leukemia by functioning as a coactivator for key transcription factors. Genes Dev. 29:2123–2139. 2015. View Article : Google Scholar : PubMed/NCBI

Jiang Y, Li C, Wu Q, An P, Huang L, Wang J, Chen C, Chen X, Zhang F, Ma L, et al: Iron-dependent histone 3 lysine 9 demethylation controls B cell proliferation and humoral immune responses. Nat Commun. 10:29352019. View Article : Google Scholar : PubMed/NCBI

Brauchle M, Yao Z, Arora R, Thigale S, Clay I, Inverardi B, Fletcher J, Taslimi P, Acker MG, Gerrits B, et al: Protein complex interactor analysis and differential activity of KDM3 subfamily members towards H3K9 methylation. PLoS One. 8:e605492013. View Article : Google Scholar : PubMed/NCBI

Liu J, Liang T and Zhangsun W: KDM3A is associated with tumor metastasis and modulates colorectal cancer cell migration and invasion. Int J Biol Macromol. 126:318–325. 2019. View Article : Google Scholar : PubMed/NCBI

Wang Z, Yang X, Liu C, Li X, Zhang B, Wang B, Zhang Y, Song C, Zhang T, Liu M, et al: Acetylation of PHF5A modulates stress responses and colorectal carcinogenesis through alternative splicing-mediated upregulation of KDM3A. Mol Cell. 74:1250–1263.e6. 2019. View Article : Google Scholar : PubMed/NCBI

Li J, Yu B, Deng P, Cheng Y, Yu Y, Kevork K, Ramadoss S, Ding X, Li X and Wang CY: KDM3 epigenetically controls tumorigenic potentials of human colorectal cancer stem cells through Wnt/β-catenin signalling. Nat Commun. 8:151462017. View Article : Google Scholar : PubMed/NCBI

Wang HY, Long QY, Tang SB, Xiao Q, Gao C, Zhao QY, Li QL, Ye M, Zhang L, Li LY and Wu M: Histone demethylase KDM3A is required for enhancer activation of hippo target genes in colorectal cancer. Nucleic Acids Res. 47:2349–2364. 2019. View Article : Google Scholar : PubMed/NCBI

Ramadoss S, Guo G and Wang CY: Lysine demethylase KDM3A regulates breast cancer cell invasion and apoptosis by targeting histone and the non-histone protein p53. Oncogene. 36:47–59. 2017. View Article : Google Scholar : PubMed/NCBI

Wade MA, Jones D, Wilson L, Stockley J, Coffey K, Robson CN and Gaughan L: The histone demethylase enzyme KDM3A is a key estrogen receptor regulator in breast cancer. Nucleic Acids Res. 43:196–207. 2015. View Article : Google Scholar : PubMed/NCBI

Lee HY, Yang EG and Park H: Hypoxia enhances the expression of prostate-specific antigen by modifying the quantity and catalytic activity of Jumonji C domain-containing histone demethylases. Carcinogenesis. 34:2706–2715. 2013. View Article : Google Scholar : PubMed/NCBI

Fan L, Peng G, Sahgal N, Fazli L, Gleave M, Zhang Y, Hussain A and Qi J: Regulation of c-Myc expression by the histone demethylase JMJD1A is essential for prostate cancer cell growth and survival. Oncogene. 35:2441–2452. 2016. View Article : Google Scholar : PubMed/NCBI

Wilson S, Fan L, Sahgal N, Qi J and Filipp FV: The histone demethylase KDM3A regulates the transcriptional program of the androgen receptor in prostate cancer cells. Oncotarget. 8:30328–30343. 2017. View Article : Google Scholar : PubMed/NCBI

Li Z, Xia J, Fang M and Xu Y: Epigenetic regulation of lung cancer cell proliferation and migration by the chromatin remodeling protein BRG1. Oncogenesis. 8:662019. View Article : Google Scholar : PubMed/NCBI

Wang F and Quan Q: The long non-coding RNA SNHG4/microRNA-let-7e/KDM3A/p21 pathway is involved in the development of non-small cell lung cancer. Mol Ther Oncolytics. 20:634–645. 2020. View Article : Google Scholar : PubMed/NCBI

Dandawate P, Ghosh C, Palaniyandi K, Paul S, Rawal S, Pradhan R, Sayed AAA, Choudhury S, Standing D, Subramaniam D, et al: The histone demethylase KDM3A, increased in human pancreatic tumors, regulates expression of DCLK1 and promotes tumorigenesis in mice. Gastroenterology. 157:1646–1659.e11. 2019. View Article : Google Scholar : PubMed/NCBI

Nakatsuka T, Tateishi K, Kudo Y, Yamamoto K, Nakagawa H, Fujiwara H, Takahashi R, Miyabayashi K, Asaoka Y, Tanaka Y, et al: Impact of histone demethylase KDM3A-dependent AP-1 transactivity on hepatotumorigenesis induced by PI3K activation. Oncogene. 36:6262–6271. 2017. View Article : Google Scholar : PubMed/NCBI

Zhang Y, Pan Q and Shao Z: Tumor-suppressive role of microRNA-202-3p in hepatocellular carcinoma through the KDM3A/HOXA1/MEIS3 pathway. Front Cell Dev Biol. 8:5560042021. View Article : Google Scholar : PubMed/NCBI

Parrish JK, Sechler M, Winn RA and Jedlicka P: The histone demethylase KDM3A is a microRNA-22-regulated tumor promoter in Ewing sarcoma. Oncogene. 34:257–262. 2015. View Article : Google Scholar : PubMed/NCBI

Sechler M, Parrish JK, Birks DK and Jedlicka P: The histone demethylase KDM3A, and its downstream target MCAM, promote Ewing sarcoma cell migration and metastasis. Oncogene. 36:4150–4160. 2017. View Article : Google Scholar : PubMed/NCBI

An MJ, Kim DH, Kim CH, Kim M, Rhee S, Seo SB and Kim JW: Histone demethylase KDM3B regulates the transcriptional network of cell-cycle genes in hepatocarcinoma HepG2 cells. Biochem Biophys Res Commun. 508:576–582. 2019. View Article : Google Scholar : PubMed/NCBI

Saraç H, Morova T, Pires E, McCullagh J, Kaplan A, Cingöz A, Bagci-Onder T, Önder T, Kawamura A and Lack NA: Systematic characterization of chromatin modifying enzymes identifies KDM3B as a critical regulator in castration resistant prostate cancer. Oncogene. 39:2187–2201. 2020. View Article : Google Scholar : PubMed/NCBI

Hu A, Hong F, Li D, Xie Q, Chen K, Zhu L and He H: KDM3B-ETF1 fusion gene downregulates LMO2 via the WNT/β-catenin signaling pathway, promoting metastasis of invasive ductal carcinoma. Cancer Gene Ther. 29:215–224. 2022. View Article : Google Scholar : PubMed/NCBI

Kim JY, Kim KB, Eom GH, Choe N, Kee HJ, Son HJ, Oh ST, Kim DW, Pak JH, Baek HJ, et al: KDM3B is the H3K9 demethylase involved in transcriptional activation of lmo2 in leukemia. Mol Cell Biol. 32:2917–2933. 2012. View Article : Google Scholar : PubMed/NCBI

Wang X, Fan H, Xu C, Jiang G, Wang H and Zhang J: KDM3B suppresses APL progression by restricting chromatin accessibility and facilitating the ATRA-mediated degradation of PML/RARα. Cancer Cell Int. 19:2562019. View Article : Google Scholar : PubMed/NCBI

Xu X, Wang L, Hu L, Dirks WG, Zhao Y, Wei Z, Chen D, Li Z, Wang Z, Han Y, et al: Small molecular modulators of JMJD1C preferentially inhibit growth of leukemia cells. Int J Cancer. 146:400–412. 2020. View Article : Google Scholar : PubMed/NCBI

Cai Y, Fu X and Deng Y: Histone demethylase JMJD1C regulates esophageal cancer proliferation Via YAP1 signaling. Am J Cancer Res. 7:115–124. 2017.PubMed/NCBI

Chen C, Aihemaiti M, Zhang X, Qu H, Sun QL, He QS and Yu WB: Downregulation of histone demethylase JMJD1C inhibits colorectal cancer metastasis through targeting ATF2. Am J Cancer Res. 8:852–865. 2018.PubMed/NCBI

Lee DH, Kim GW, Jeon YH, Yoo J, Lee SW and Kwon SH: Advances in histone demethylase KDM4 as cancer therapeutic targets. FASEB J. 34:3461–3484. 2020. View Article : Google Scholar : PubMed/NCBI

Berry WL, Shin S, Lightfoot SA and Janknecht R: Oncogenic features of the JMJD2A histone demethylase in breast cancer. Int J Oncol. 41:1701–1706. 2012. View Article : Google Scholar : PubMed/NCBI

Kim TD, Fuchs JR, Schwartz E, Abdelhamid D, Etter J, Berry WL, Li C, Ihnat MA, Li PK and Janknecht R: Pro-growth role of the JMJD2C histone demethylase in HCT-116 colon cancer cells and identification of curcuminoids as JMJD2 inhibitors. Am J Transl Res. 6:236–247. 2014.PubMed/NCBI

Ye Q, Holowatyj A, Wu J, Liu H, Zhang L, Suzuki T and Yang ZQ: Genetic alterations of KDM4 subfamily and therapeutic effect of novel demethylase inhibitor in breast cancer. Am J Cancer Res. 5:1519–1530. 2015.PubMed/NCBI

Li X and Dong S: Histone demethylase JMJD2B and JMJD2C induce fibroblast growth factor 2: Mediated tumorigenesis of osteosarcoma. Med Oncol. 32:532015. View Article : Google Scholar : PubMed/NCBI

Kim TD, Jin F, Shin S, Oh S, Lightfoot SA, Grande JP, Johnson AJ, van Deursen JM, Wren JD and Janknecht R: Histone demethylase JMJD2A drives prostate tumorigenesis through transcription factor ETV1. J Clin Invest. 126:706–720. 2016. View Article : Google Scholar : PubMed/NCBI

Sun S, Yang F, Zhu Y and Zhang S: KDM4A promotes the growth of non-small cell lung cancer by mediating the expression of Myc via DLX5 through the Wnt/β-catenin signaling pathway. Life Sci. 262:1185082020. View Article : Google Scholar : PubMed/NCBI

Hu CE, Liu YC, Zhang HD and Huang GJ: JMJD2A predicts prognosis and regulates cell growth in human gastric cancer. Biochem Biophys Res Commun. 449:1–7. 2014. View Article : Google Scholar : PubMed/NCBI

Yang J, Jubb AM, Pike L, Buffa FM, Turley H, Baban D, Leek R, Gatter KC, Ragoussis J and Harris AL: The histone demethylase JMJD2B is regulated by estrogen receptor alpha and hypoxia, and is a key mediator of estrogen induced growth. Cancer Res. 70:6456–6466. 2010. View Article : Google Scholar : PubMed/NCBI

Fu L, Chen L, Yang J, Ye T, Chen Y and Fang J: HIF-1α-induced histone demethylase JMJD2B contributes to the malignant phenotype of colorectal cancer cells via an epigenetic mechanism. Carcinogenesis. 33:1664–1673. 2012. View Article : Google Scholar : PubMed/NCBI

Li H, Lan J, Wang G, Guo K, Han C, Li X, Hu J, Cao Z and Luo X: KDM4B facilitates colorectal cancer growth and glucose metabolism by stimulating TRAF6-mediated AKT activation. J Exp Clin Cancer Res. 39:122020. View Article : Google Scholar : PubMed/NCBI

Tan J, Wang HL, Yang J, Liu QQ, Li CM, Wang YQ, Fu LN, Gao QY, Chen YX and Fang JY: JMJD2B-induced amino acid alterations enhance the survival of colorectal cancer cells under glucose-deprivation via autophagy. Theranostics. 10:5763–5777. 2020. View Article : Google Scholar : PubMed/NCBI

Fu LN, Wang YQ, Tan J, Xu J, Gao QY, Chen YX and Fang JY: Role of JMJD2B in colon cancer cell survival under glucose-deprived conditions and the underlying mechanisms. Oncogene. 37:389–402. 2018. View Article : Google Scholar : PubMed/NCBI

Wissmann M, Yin N, Müller JM, Greschik H, Fodor BD, Jenuwein T, Vogler C, Schneider R, Günther T, Buettner R, et al: Cooperative demethylation by JMJD2C and LSD1 promotes androgen receptor-dependent gene expression. Nat Cell Biol. 9:347–353. 2007. View Article : Google Scholar : PubMed/NCBI

Lee DH, Kim GW, Yoo J, Lee SW, Jeon YH, Kim SY, Kang HG, Kim DH, Chun KH, Choi J and Kwon SH: Histone demethylase KDM4C controls tumorigenesis of glioblastoma by epigenetically regulating p53 and c-Myc. Cell Death Dis. 12:892021. View Article : Google Scholar : PubMed/NCBI

Luo W, Chang R, Zhong J, Pandey A and Semenza GL: Histone demethylase JMJD2C is a coactivator for hypoxia-inducible factor 1 that is required for breast cancer progression. Proc Natl Acad Sci USA. 109:E3367–E3376. 2012. View Article : Google Scholar : PubMed/NCBI

Yang D, Xu T, Fan L, Liu K and Li G: microRNA-216b enhances cisplatin-induced apoptosis in osteosarcoma MG63 and SaOS-2 cells by binding to JMJD2C and regulating the HIF1α/HES1 signaling axis. J Exp Clin Cancer Res. 39:2012020. View Article : Google Scholar : PubMed/NCBI

Wu X, Deng Y, Zu Y and Yin J: Histone demethylase KDM4C activates HIF1α/VEGFA signaling through the costimulatory factor STAT3 in NSCLC. Am J Cancer Res. 10:491–506. 2020.PubMed/NCBI

Hu F, Li H, Liu L, Xu F, Lai S, Luo X, Hu J and Yang X: Histone demethylase KDM4D promotes gastrointestinal stromal tumor progression through HIF1β/VEGFA signalling. Mol Cancer. 17:1072018. View Article : Google Scholar : PubMed/NCBI

Peng K, Zhuo M, Li M, Chen Q, Mo P and Yu C: Histone demethylase JMJD2D activates HIF1 signaling pathway via multiple mechanisms to promote colorectal cancer glycolysis and progression. Oncogene. 39:7076–7091. 2020. View Article : Google Scholar : PubMed/NCBI

Zhuo M, Chen W, Shang S, Guo P, Peng K, Li M, Mo P, Zhang Y, Qiu X, Li W and Yu C: Inflammation-induced JMJD2D promotes colitis recovery and colon tumorigenesis by activating Hedgehog signaling. Oncogene. 39:3336–3353. 2020. View Article : Google Scholar : PubMed/NCBI

Peng K, Kou L, Yu L, Bai C, Li M, Mo P, Li W and Yu C: Histone demethylase JMJD2D interacts with β-catenin to induce transcription and activate colorectal cancer cell proliferation and tumor growth in mice. Gastroenterology. 156:1112–1126. 2019. View Article : Google Scholar : PubMed/NCBI

Li M, Deng Y, Zhuo M, Zhou H, Kong X, Xia X, Su Z, Chen Q, Guo P, Mo P, et al: Demethylase-independent function of JMJD2D as a novel antagonist of p53 to promote liver cancer initiation and progression. Theranostics. 10:8863–8879. 2020. View Article : Google Scholar : PubMed/NCBI

Pilka ES, James T and Lisztwan JH: Structural definitions of Jumonji family demethylase selectivity. Drug Discov Today. 20:743–749. 2015. View Article : Google Scholar : PubMed/NCBI

Horton JR, Engstrom A, Zoeller EL, Liu X, Shanks JR, Zhang X, Johns MA, Vertino PM, Fu H and Cheng X: Characterization of a linked Jumonji domain of the KDM5/JARID1 family of histone H3 lysine 4 demethylases. J Biol Chem. 291:2631–2646. 2016. View Article : Google Scholar : PubMed/NCBI

Plch J, Hrabeta J and Eckschlager T: KDM5 demethylases and their role in cancer cell chemoresistance. Int J Cancer. 144:221–231. 2019. View Article : Google Scholar : PubMed/NCBI

Yang GJ, Zhu MH, Lu XJ, Liu YJ, Lu JF, Leung CH, Ma DL and Chen J: The emerging role of KDM5A in human cancer. J Hematol Oncol. 14:302021. View Article : Google Scholar : PubMed/NCBI

Teng YC, Lee CF, Li YS, Chen YR, Hsiao PW, Chan MY, Lin FM, Huang HD, Chen YT, Jeng YM, et al: Histone demethylase RBP2 promotes lung tumorigenesis and cancer metastasis. Cancer Res. 73:4711–4721. 2013. View Article : Google Scholar : PubMed/NCBI

Liang X, Zeng J, Wang L, Fang M, Wang Q, Zhao M, Xu X, Liu Z, Li W, Liu S, et al: Histone demethylase retinoblastoma binding protein 2 is overexpressed in hepatocellular carcinoma and negatively regulated by hsa-miR-212. PLoS One. 8:e697842013. View Article : Google Scholar : PubMed/NCBI

Yang GJ, Wang W, Mok SWF, Wu C, Law BYK, Miao XM, Wu KJ, Zhong HJ, Wong CY, Wong VKW, et al: Selective inhibition of lysine-specific demethylase 5A (KDM5A) using a rhodium(III) complex for triple-negative breast cancer therapy. Angew Chem Int Ed Engl. 57:13091–13095. 2018. View Article : Google Scholar : PubMed/NCBI

Yang GJ, Ko CN, Zhong HJ, Leung CH and Ma DL: Structure-Based discovery of a selective KDM5A inhibitor that exhibits anti-cancer activity via inducing cell cycle arrest and senescence in breast cancer cell lines. Cancers (Basel). 11:922019. View Article : Google Scholar : PubMed/NCBI

Lin W, Watanabe H, Peng S, Francis JM, Kaplan N, Pedamallu CS, Ramachandran A, Agoston A, Bass AJ and Meyerson M: Dynamic epigenetic regulation by menin during pancreatic islet tumor formation. Mol Cancer Res. 13:689–698. 2015. View Article : Google Scholar : PubMed/NCBI

Oser MG, Sabet AH, Gao W, Chakraborty AA, Schinzel AC, Jennings RB, Fonseca R, Bonal DM, Booker MA, Flaifel A, et al: The KDM5A/RBP2 histone demethylase represses NOTCH signaling to sustain neuroendocrine differentiation and promote small cell lung cancer tumorigenesis. Genes Dev. 33:1718–1738. 2019. View Article : Google Scholar : PubMed/NCBI

Yamamoto S, Wu Z, Russnes HG, Takagi S, Peluffo G, Vaske C, Zhao X, Moen Vollan HK, Maruyama R, Ekram MB, et al: JARID1B is a luminal lineage-driving oncogene in breast cancer. Cancer Cell. 25:762–777. 2014. View Article : Google Scholar : PubMed/NCBI

Yamane K, Tateishi K, Klose RJ, Fang J, Fabrizio LA, Erdjument-Bromage H, Taylor-Papadimitriou J, Tempst P and Zhang Y: PLU-1 is an H3K4 demethylase involved in transcriptional repression and breast cancer cell proliferation. Mol Cell. 25:801–812. 2007. View Article : Google Scholar : PubMed/NCBI

Tortelli TC, Tamura RE, de Souza Junqueira M, da Silva Mororó J, Bustos SO, Natalino RJM, Russell S, Désaubry L, Strauss BE and Chammas R: Metformin-induced chemosensitization to cisplatin depends on P53 status and is inhibited by Jarid1b overexpression in non-small cell lung cancer cells. Aging (Albany NY). 13:21914–21940. 2021. View Article : Google Scholar : PubMed/NCBI

Kuo KT, Huang WC, Bamodu OA, Lee WH, Wang CH, Hsiao M, Wang LS and Yeh CT: Histone demethylase JARID1B/KDM5B promotes aggressiveness of non-small cell lung cancer and serves as a good prognostic predictor. Clin Epigenetics. 10:1072018. View Article : Google Scholar : PubMed/NCBI

Wang D, Han S, Peng R, Jiao C, Wang X, Yang X, Yang R and Li X: Depletion of histone demethylase KDM5B inhibits cell proliferation of hepatocellular carcinoma by regulation of cell cycle checkpoint proteins p15 and p27. J Exp Clin Cancer Res. 35:372016. View Article : Google Scholar : PubMed/NCBI

Hayami S, Yoshimatsu M, Veerakumarasivam A, Unoki M, Iwai Y, Tsunoda T, Field HI, Kelly JD, Neal DE, Yamaue H, et al: Overexpression of the JmjC histone demethylase KDM5B in human carcinogenesis: Involvement in the proliferation of cancer cells through the E2F/RB pathway. Mol Cancer. 9:592010. View Article : Google Scholar : PubMed/NCBI

Huang YQ, Zou Y, Zheng RJ and Ma XD: Down-regulation of JARID1B expression inhibits cell proliferation, induces apoptosis and blocks cell cycle in human acute lymphoblastic leukemia cells. Eur Rev Med Pharmacol Sci. 22:1366–1373. 2018.PubMed/NCBI

Xiang Y, Zhu Z, Han G, Ye X, Xu B, Peng Z, Ma Y, Yu Y, Lin H, Chen AP and Chen CD: JARID1B is a histone H3 lysine 4 demethylase up-regulated in prostate cancer. Proc Natl Acad Sci USA. 104:19226–19231. 2007. View Article : Google Scholar : PubMed/NCBI

Yan G, Li S, Yue M, Li C and Kang Z: Lysine demethylase 5B suppresses CC chemokine ligand 14 to promote progression of colorectal cancer through the Wnt/β-catenin pathway. Life Sci. 264:1187262021. View Article : Google Scholar : PubMed/NCBI

Niu X, Zhang T, Liao L, Zhou L, Lindner DJ, Zhou M, Rini B, Yan Q and Yang H: The von Hippel-Lindau tumor suppressor protein regulates gene expression and tumor growth through histone demethylase JARID1C. Oncogene. 31:776–786. 2012. View Article : Google Scholar : PubMed/NCBI

Rondinelli B, Rosano D, Antonini E, Frenquelli M, Montanini L, Huang D, Segalla S, Yoshihara K, Amin SB, Lazarevic D, et al: Histone demethylase JARID1C inactivation triggers genomic instability in sporadic renal cancer. J Clin Invest. 125:4625–4637. 2015. View Article : Google Scholar : PubMed/NCBI

Zheng Q, Li P, Zhou X, Qiang Y, Fan J, Lin Y, Chen Y, Guo J, Wang F, Xue H, et al: Deficiency of the X-inactivation escaping gene KDM5C in clear cell renal cell carcinoma promotes tumorigenicity by reprogramming glycogen metabolism and inhibiting ferroptosis. Theranostics. 11:8674–8691. 2021. View Article : Google Scholar : PubMed/NCBI

Zhang B, Zhou BH, Xiao M, Li H, Guo L, Wang MX, Yu SH and Ye QH: KDM5C represses FASN-mediated lipid metabolism to exert tumor suppressor activity in intrahepatic cholangiocarcinoma. Front Oncol. 10:10252020. View Article : Google Scholar : PubMed/NCBI

Zhang Q, Xu L, Wang J, Zhu X, Ma Z, Yang J, Li J, Jia X and Wei L: KDM5C expedites lung cancer growth and metastasis through epigenetic regulation of MicroRNA-133a. Onco Targets Ther. 14:1187–1204. 2021. View Article : Google Scholar : PubMed/NCBI

Ji X, Jin S, Qu X, Li K, Wang H, He H, Guo F and Dong L: Lysine-specific demethylase 5C promotes hepatocellular carcinoma cell invasion through inhibition BMP7 expression. BMC Cancer. 15:8012015. View Article : Google Scholar : PubMed/NCBI

Lin H, Ma N, Zhao L, Yang G and Cao B: KDM5c promotes colon cancer cell proliferation through the FBXW7-c-Jun regulatory axis. Front Oncol. 10:5354492020. View Article : Google Scholar : PubMed/NCBI

Shen HF, Zhang WJ, Huang Y, He YH, Hu GS, Wang L, Peng BL, Yi J, Li TT, Rong R, et al: The dual function of KDM5C in both gene transcriptional activation and repression promotes breast cancer cell growth and tumorigenesis. Adv Sci (Weinh). 8:20046352021. View Article : Google Scholar : PubMed/NCBI

Jangravi Z, Tabar MS, Mirzaei M, Parsamatin P, Vakilian H, Alikhani M, Shabani M, Haynes PA, Goodchild AK, Gourabi H, et al: Two splice variants of Y chromosome-located lysine-specific demethylase 5D have distinct function in prostate cancer cell line (DU-145). J Proteome Res. 14:3492–3502. 2015. View Article : Google Scholar : PubMed/NCBI

Li N, Dhar SS, Chen TY, Kan PY, Wei Y, Kim JH, Chan CH, Lin HK, Hung MC and Lee MG: JARID1D is a suppressor and prognostic marker of prostate cancer invasion and metastasis. Cancer Res. 76:831–843. 2016. View Article : Google Scholar : PubMed/NCBI

Shen X, Hu K, Cheng G, Xu L, Chen Z, Du P and Zhuang Z: KDM5D inhibit epithelial-mesenchymal transition of gastric cancer through demethylation in the promoter of Cul4A in male. J Cell Biochem. 120:12247–12258. 2019. View Article : Google Scholar : PubMed/NCBI

Cai LS, Chen QX, Fang SY, Lian MQ, Lian MJ and Cai MZ: ETV4 promotes the progression of gastric cancer through regulating KDM5D. Eur Rev Med Pharmacol Sci. 24:2442–2451. 2020.PubMed/NCBI

Willis-Owen SAG, Domingo-Sabugo C, Starren E, Liang L, Freidin MB, Arseneault M, Zhang Y, Lu SK, Popat S, Lim E, et al: Y disruption, autosomal hypomethylation and poor male lung cancer survival. Sci Rep. 11:124532021. View Article : Google Scholar : PubMed/NCBI

Schulz WA, Lang A, Koch J and Greife A: The histone demethylase UTX/KDM6A in cancer: Progress and puzzles. Int J Cancer. 145:614–620. 2019. View Article : Google Scholar : PubMed/NCBI

Walport LJ, Hopkinson RJ, Vollmar M, Madden SK, Gileadi C, Oppermann U, Schofield CJ and Johansson C: Human UTY(KDM6C) is a male-specific N-methyl lysyl demethylase. J Biol Chem. 289:18302–18313. 2014. View Article : Google Scholar : PubMed/NCBI

Sengoku T and Yokoyama S: Structural basis for histone H3 Lys 27 demethylation by UTX/KDM6A. Genes Dev. 25:2266–2277. 2011. View Article : Google Scholar : PubMed/NCBI

Li Y, Yang J, Zhang X, Liu H and Guo J: KDM6A suppresses hepatocellular carcinoma cell proliferation by negatively regulating the TGF-β/SMAD signaling pathway. Exp Ther Med. 20:2774–2782. 2020.PubMed/NCBI

Ler LD, Ghosh S, Chai X, Thike AA, Heng HL, Siew EY, Dey S, Koh LK, Lim JQ, Lim WK, et al: Loss of tumor suppressor KDM6A amplifies PRC2-regulated transcriptional repression in bladder cancer and can be targeted through inhibition of EZH2. Sci Transl Med. 9:eaai83122017. View Article : Google Scholar : PubMed/NCBI

Zhang J, Ying Y, Li M, Wang M, Huang X, Jia M, Zeng J, Ma C, Zhang Y, Li C, et al: Targeted inhibition of KDM6 histone demethylases eradicates tumor-initiating cells via enhancer reprogramming in colorectal cancer. Theranostics. 10:10016–10030. 2020. View Article : Google Scholar : PubMed/NCBI

Romero OA, Vilarrubi A, Alburquerque-Bejar JJ, Gomez A, Andrades A, Trastulli D, Pros E, Setien F, Verdura S, Farré L, et al: SMARCA4 deficient tumours are vulnerable to KDM6A/UTX and KDM6B/JMJD3 blockade. Nat Commun. 12:43192021. View Article : Google Scholar : PubMed/NCBI

Chaturvedi SS, Ramanan R, Waheed SO, Karabencheva-Christova TG and Christov CZ: Structure-function relationships in KDM7 histone demethylases. Adv Protein Chem Struct Biol. 117:113–125. 2019. View Article : Google Scholar : PubMed/NCBI

Park SY, Park JW and Chun YS: Jumonji histone demethylases as emerging therapeutic targets. Pharmacol Res. 105:146–151. 2016. View Article : Google Scholar : PubMed/NCBI

Osawa T, Muramatsu M, Wang F, Tsuchida R, Kodama T, Minami T and Shibuya M: Increased expression of histone demethylase JHDM1D under nutrient starvation suppresses tumor growth via down-regulating angiogenesis. Proc Natl Acad Sci USA. 108:20725–20729. 2011. View Article : Google Scholar : PubMed/NCBI

Lee KH, Hong S, Kang M, Jeong CW, Ku JH, Kim HH and Kwak C: Histone demethylase KDM7A controls androgen receptor activity and tumor growth in prostate cancer. Int J Cancer. 143:2849–2861. 2018. View Article : Google Scholar : PubMed/NCBI

Zhang Z, Chen B, Zhu Y, Zhang T, Zhang X, Yuan Y and Xu Y: The Jumonji domain-containing histone demethylase homolog 1D/lysine demethylase 7A (JHDM1D/KDM7A) is an epigenetic activator of RHOJ transcription in breast cancer cells. Front Cell Dev Biol. 9:6643752021. View Article : Google Scholar : PubMed/NCBI

Tong D, Liu Q, Liu G, Yuan W, Wang L, Guo Y, Lan W, Zhang D, Dong S, Wang Y, et al: The HIF/PHF8/AR axis promotes prostate cancer progression. Oncogenesis. 5:e2832016. View Article : Google Scholar : PubMed/NCBI

Li S, Sun A, Liang X, Ma L, Shen L, Li T, Zheng L, Shang W, Zhao W and Jia J: Histone demethylase PHF8 promotes progression and metastasis of gastric cancer. Am J Cancer Res. 7:448–461. 2017. View Article : Google Scholar : PubMed/NCBI

Zhou W, Gong L, Wu Q, Xing C, Wei B, Chen T, Zhou Y, Yin S, Jiang B, Xie H, et al: PHF8 upregulation contributes to autophagic degradation of E-cadherin, epithelial-mesenchymal transition and metastasis in hepatocellular carcinoma. J Exp Clin Cancer Res. 37:2152018. View Article : Google Scholar : PubMed/NCBI

Tseng LL, Cheng HH, Yeh TS, Huang SC, Syu YY, Chuu CP, Yuh CH, Kung HJ and Wang WC: Targeting the histone demethylase PHF8-mediated PKCα-Src-PTEN axis in HER2-negative gastric cancer. Proc Natl Acad Sci USA. 117:24859–24866. 2020. View Article : Google Scholar : PubMed/NCBI

Shao P, Liu Q, Maina PK, Cui J, Bair TB, Li T, Umesalma S, Zhang W and Qi HH: Histone demethylase PHF8 promotes epithelial to mesenchymal transition and breast tumorigenesis. Nucleic Acids Res. 45:1687–1702. 2017. View Article : Google Scholar : PubMed/NCBI

Liu Q, Pang J, Wang LA, Huang Z, Xu J, Yang X, Xie Q, Huang Y, Tang T, Tong D, et al: Histone demethylase PHF8 drives neuroendocrine prostate cancer progression by epigenetically upregulating FOXA2. J Pathol. 253:106–118. 2021. View Article : Google Scholar : PubMed/NCBI

Fu Y, Liu M, Li F, Qian L, Zhang P, Lv F, Cheng W and Hou R: miR-221 promotes hepatocellular carcinoma cells migration via targeting PHF2. Biomed Res Int. 2019:43714052019. View Article : Google Scholar : PubMed/NCBI

Lee KH, Park JW, Sung HS, Choi YJ, Kim WH, Lee HS, Chung HJ, Shin HW, Cho CH, Kim TY, et al: PHF2 histone demethylase acts as a tumor suppressor in association with p53 in cancer. Oncogene. 34:2897–2909. 2015. View Article : Google Scholar : PubMed/NCBI

Del Rizzo PA, Krishnan S and Trievel RC: Crystal structure and functional analysis of JMJD5 indicate an alternate specificity and function. Mol Cell Biol. 32:4044–4052. 2012. View Article : Google Scholar : PubMed/NCBI

Hsia DA, Tepper CG, Pochampalli MR, Hsia EY, Izumiya C, Huerta SB, Wright ME, Chen HW, Kung HJ and Izumiya Y: KDM8, a H3K36me2 histone demethylase that acts in the cyclin A1 coding region to regulate cancer cell proliferation. Proc Natl Acad Sci USA. 107:9671–9676. 2010. View Article : Google Scholar : PubMed/NCBI

Yao Y, Zhou WY and He RX: Down-regulation of JMJD5 suppresses metastasis and induces apoptosis in oral squamous cell carcinoma by regulating p53/NF-κB pathway. Biomed Pharmacother. 109:1994–2004. 2019. View Article : Google Scholar : PubMed/NCBI

Chang WH, Forde D and Lai AG: Dual prognostic role of 2-oxoglutarate-dependent oxygenases in ten cancer types: Implications for cell cycle regulation and cell adhesion maintenance. Cancer Commun (Lond). 39:232019. View Article : Google Scholar : PubMed/NCBI

Wu LW, Zhou DM, Zhang ZY, Zhang JK, Zhu HJ, Lin NM and Zhang C: Suppression of LSD1 enhances the cytotoxic and apoptotic effects of regorafenib in hepatocellular carcinoma cells. Biochem Biophys Res Commun. 512:852–858. 2019. View Article : Google Scholar : PubMed/NCBI

Verigos J, Karakaidos P, Kordias D, Papoudou-Bai A, Evangelou Z, Harissis HV, Klinakis A and Magklara A: The histone demethylase LSD1/ΚDM1A mediates chemoresistance in breast cancer via regulation of a stem cell program. Cancers (Basel). 11:15852019. View Article : Google Scholar : PubMed/NCBI

Lee YK, Lim J, Yoon SY, Joo JC, Park SJ and Park YJ: Promotion of cell death in cisplatin-resistant ovarian cancer cells through KDM1B-DCLRE1B modulation. Int J Mol Sci. 20:24432019. View Article : Google Scholar : PubMed/NCBI

Tang D, He J, Dai Y, Geng X, Leng Q, Jiang H, Sun R and Xu S: Targeting KDM1B-dependent miR-215-AR-AGR2-axis promotes sensitivity to enzalutamide-resistant prostate cancer. Cancer Gene Ther. 29:543–557. 2022. View Article : Google Scholar : PubMed/NCBI

Tang DE, Dai Y, He JX, Lin LW, Leng QX, Geng XY, Fu DX, Jiang HW and Xu SH: Targeting the KDM4B-AR-c-Myc axis promotes sensitivity to androgen receptor-targeted therapy in advanced prostate cancer. J Pathol. 252:101–113. 2020. View Article : Google Scholar : PubMed/NCBI

Hou J, Wu J, Dombkowski A, Zhang K, Holowatyj A, Boerner JL and Yang ZQ: Genomic amplification and a role in drug-resistance for the KDM5A histone demethylase in breast cancer. Am J Transl Res. 4:247–256. 2012.PubMed/NCBI

Banelli B, Carra E, Barbieri F, Würth R, Parodi F, Pattarozzi A, Carosio R, Forlani A, Allemanni G, Marubbi D, et al: The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma. Cell Cycle. 14:3418–3429. 2015. View Article : Google Scholar : PubMed/NCBI

Xu W, Zhou B, Zhao X, Zhu L, Xu J, Jiang Z, Chen D, Wei Q, Han M, Feng L, et al: KDM5B demethylates H3K4 to recruit XRCC1 and promote chemoresistance. Int J Biol Sci. 14:1122–1132. 2018. View Article : Google Scholar : PubMed/NCBI

Roesch A, Vultur A, Bogeski I, Wang H, Zimmermann KM, Speicher D, Körbel C, Laschke MW, Gimotty PA, Philipp SE, et al: Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells. Cancer Cell. 23:811–825. 2013. View Article : Google Scholar : PubMed/NCBI

Liu X, Zhang SM, McGeary MK, Krykbaeva I, Lai L, Jansen DJ, Kales SC, Simeonov A, Hall MD, Kelly DP, et al: KDM5B promotes drug resistance by regulating melanoma-propagating cell subpopulations. Mol Cancer Ther. 18:706–717. 2019. View Article : Google Scholar : PubMed/NCBI

Hinohara K, Wu HJ, Vigneau S, McDonald TO, Igarashi KJ, Yamamoto KN, Madsen T, Fassl A, Egri SB, Papanastasiou M, et al: KDM5 histone demethylase activity links cellular transcriptomic heterogeneity to therapeutic resistance. Cancer Cell. 34:939–953.e9. 2018. View Article : Google Scholar : PubMed/NCBI

Pippa S, Mannironi C, Licursi V, Bombardi L, Colotti G, Cundari E, Mollica A, Coluccia A, Naccarato V, La Regina G, et al: Small molecule inhibitors of KDM5 histone demethylases increase the radiosensitivity of breast cancer cells overexpressing JARID1B. Molecules. 24:17392019. View Article : Google Scholar : PubMed/NCBI

Lin H, Yang G, Yu J, Wang J, Li Q, Guo S and Cao B: KDM5c inhibits multidrug resistance of colon cancer cell line by down-regulating ABCC1. Biomed Pharmacother. 107:1205–1209. 2018. View Article : Google Scholar : PubMed/NCBI

Komura K, Jeong SH, Hinohara K, Qu F, Wang X, Hiraki M, Azuma H, Lee GS, Kantoff PW and Sweeney CJ: Resistance to docetaxel in prostate cancer is associated with androgen receptor activation and loss of KDM5D expression. Proc Natl Acad Sci USA. 113:6259–6264. 2016. View Article : Google Scholar : PubMed/NCBI

He C, Sun J, Liu C, Jiang Y and Hao Y: Elevated H3K27me3 levels sensitize osteosarcoma to cisplatin. Clin Epigenetics. 11:82019. View Article : Google Scholar : PubMed/NCBI

Wang Q, Chen X, Jiang Y, Liu S, Liu H, Sun X, Zhang H, Liu Z, Tao Y, Li C, et al: Elevating H3K27me3 level sensitizes colorectal cancer to oxaliplatin. J Mol Cell Biol. 12:125–137. 2020. View Article : Google Scholar : PubMed/NCBI

Mathur R, Sehgal L, Havranek O, Köhrer S, Khashab T, Jain N, Burger JA, Neelapu SS, Davis RE and Samaniego F: Inhibition of demethylase KDM6B sensitizes diffuse large B-cell lymphoma to chemotherapeutic drugs. Haematologica. 102:373–380. 2017. View Article : Google Scholar : PubMed/NCBI

Zhang C, Shen L, Zhu Y, Xu R, Deng Z, Liu X, Ding Y, Wang C, Shi Y, Bei L, et al: KDM6A promotes imatinib resistance through YY1-mediated transcriptional upregulation of TRKA independently of its demethylase activity in chronic myelogenous leukemia. Theranostics. 11:2691–2705. 2021. View Article : Google Scholar : PubMed/NCBI

Macedo-Silva C, Miranda-Goncalves V, Lameirinhas A, Lencart J, Pereira A, Lobo J, Guimarães R, Martins AT, Henrique R, Bravo I and Jerónimo C: JmjC-KDMs KDM3A and KDM6B modulate radioresistance under hypoxic conditions in esophageal squamous cell carcinoma. Cell Death Dis. 11:10682020. View Article : Google Scholar : PubMed/NCBI

Xu S, Fan L, Jeon HY, Zhang F, Cui X, Mickle MB, Peng G, Hussain A, Fazli L, Gleave ME, et al: p300-mediated acetylation of histone demethylase JMJD1A prevents its degradation by ubiquitin ligase STUB1 and enhances its activity in prostate cancer. Cancer Res. 80:3074–3087. 2020. View Article : Google Scholar : PubMed/NCBI

McAllister TE, England KS, Hopkinson RJ, Brennan PE, Kawamura A and Schofield CJ: Recent progress in histone demethylase inhibitors. J Med Chem. 59:1308–1329. 2016. View Article : Google Scholar : PubMed/NCBI

Fang Y, Liao G and Yu B: LSD1/KDM1A inhibitors in clinical trials: Advances and prospects. J Hematol Oncol. 12:1292019. View Article : Google Scholar : PubMed/NCBI

Fu DJ, Li J and Yu B: Annual review of LSD1/KDM1A inhibitors in 2020. Eur J Med Chem. 214:1132542021. View Article : Google Scholar : PubMed/NCBI

Kleszcz R, Skalski M, Krajka-Kuźniak V and Paluszczak J: The inhibitors of KDM4 and KDM6 histone lysine demethylases enhance the anti-growth effects of erlotinib and HS-173 in head and neck cancer cells. Eur J Pharm Sci. 166:1059612021. View Article : Google Scholar : PubMed/NCBI

Illiano M, Conte M, Salzillo A, Ragone A, Spina A, Nebbioso A, Altucci L, Sapio L and Naviglio S: The KDM inhibitor GSKJ4 triggers CREB downregulation via a protein kinase A and proteasome-dependent mechanism in human acute myeloid leukemia cells. Front Oncol. 10:7992020. View Article : Google Scholar : PubMed/NCBI

Yang GJ, Wu J, Miao L, Zhu MH, Zhou QJ, Lu XJ, Lu JF, Leung CH, Ma DL and Chen J: Pharmacological inhibition of KDM5A for cancer treatment. Eur J Med Chem. 226:1138552021. View Article : Google Scholar : PubMed/NCBI

Baby S, Gurukkala Valapil D and Shankaraiah N: Unravelling KDM4 histone demethylase inhibitors for cancer therapy. Drug Discov Today. 26:1841–1856. 2021. View Article : Google Scholar : PubMed/NCBI

Varghese B, Del Gaudio N, Cobellis G, Altucci L and Nebbioso A: KDM4 involvement in breast cancer and possible therapeutic approaches. Front Oncol. 11:7503152021. View Article : Google Scholar : PubMed/NCBI

Carter DM, Specker E, Małecki PH, Przygodda J, Dudaniec K, Weiss MS, Heinemann U, Nazaré M and Gohlke U: Enhanced properties of a benzimidazole benzylpyrazole lysine demethylase inhibitor: Mechanism-of-action, binding site analysis, and activity in cellular models of prostate cancer. J Med Chem. 64:14266–14282. 2021. View Article : Google Scholar : PubMed/NCBI

Souto JA, Sarno F, Nebbioso A, Papulino C, Álvarez R, Lombino J, Perricone U, Padova A, Altucci L and de Lera ÁR: A new family of Jumonji C domain-containing KDM inhibitors inspired by natural product purpurogallin. Front Chem. 8:3122020. View Article : Google Scholar : PubMed/NCBI

Tayari MM, Santos HGD, Kwon D, Bradley TJ, Thomassen A, Chen C, Dinh Y, Perez A, Zelent A, Morey L, et al: Clinical responsiveness to all-trans retinoic acid is potentiated by LSD1 inhibition and associated with a quiescent transcriptome in myeloid malignancies. Clin Cancer Res. 27:1893–1903. 2021. View Article : Google Scholar : PubMed/NCBI

Cuyàs E, Gumuzio J, Verdura S, Brunet J, Bosch-Barrera J, Martin-Castillo B, Alarcón T, Encinar JA, Martin ÁG and Menendez JA: The LSD1 inhibitor iadademstat (ORY-1001) targets SOX2-driven breast cancer stem cells: A potential epigenetic therapy in luminal-B and HER2-positive breast cancer subtypes. Aging (Albany NY). 12:4794–4814. 2020. View Article : Google Scholar : PubMed/NCBI

Wang T, Zhang F and Sun F: ORY-1001, a KDM1A inhibitor, inhibits proliferation, and promotes apoptosis of triple negative breast cancer cells by inactivating androgen receptor. Drug Dev Res. 83:208–216. 2022. View Article : Google Scholar : PubMed/NCBI

Maes T, Mascaró C, Tirapu I, Estiarte A, Ciceri F, Lunardi S, Guibourt N, Perdones A, Lufino MMP, Somervaille TCP, et al: ORY-1001, a potent and selective covalent KDM1A inhibitor, for the treatment of acute leukemia. Cancer Cell. 33:495–511.e12. 2018. View Article : Google Scholar : PubMed/NCBI

Salamero O, Montesinos P, Willekens C, Pérez-Simón JA, Pigneux A, Récher C, Popat R, Carpio C, Molinero C, Mascaró C, et al: First-in-human phase I study of iadademstat (ORY-1001): A first-in-class lysine-specific histone demethylase 1A inhibitor, in relapsed or refractory acute myeloid leukemia. J Clin Oncol. 38:4260–4273. 2020. View Article : Google Scholar : PubMed/NCBI

Huang M, Chen C, Geng J, Han D, Wang T, Xie T, Wang L, Wang Y, Wang C, Lei Z and Chu X: Targeting KDM1A attenuates Wnt/β-catenin signaling pathway to eliminate sorafenib-resistant stem-like cells in hepatocellular carcinoma. Cancer Lett. 398:12–21. 2017. View Article : Google Scholar : PubMed/NCBI

Lillico R, Lawrence CK and Lakowski TM: Selective DOT1L, LSD1, and HDAC class I inhibitors reduce HOXA9 expression in MLL-AF9 rearranged leukemia cells, but dysregulate the expression of many histone-modifying enzymes. J Proteome Res. 17:2657–2667. 2018. View Article : Google Scholar : PubMed/NCBI

Bauer TM, Besse B, Martinez-Marti A, Trigo JM, Moreno V, Garrido P, Ferron-Brady G, Wu Y, Park J, Collingwood T, et al: Phase I, open-label, dose-escalation study of the safety, pharmacokinetics, pharmacodynamics, and efficacy of GSK2879552 in relapsed/refractory SCLC. J Thorac Oncol. 14:1828–1838. 2019. View Article : Google Scholar : PubMed/NCBI

Kanouni T, Severin C, Cho RW, Yuen NY, Xu J, Shi L, Lai C, Del Rosario JR, Stansfield RK, Lawton LN, et al: Discovery of CC-90011: A potent and selective reversible inhibitor of lysine specific demethylase 1 (LSD1). J Med Chem. 63:14522–14529. 2020. View Article : Google Scholar : PubMed/NCBI

Hollebecque A, Salvagni S, Plummer R, Isambert N, Niccoli P, Capdevila J, Curigliano G, Moreno V, Martin-Romano P, Baudin E, et al: Phase I study of lysine-specific demethylase 1 inhibitor, CC-90011, in patients with advanced solid tumors and relapsed/refractory non-Hodgkin lymphoma. Clin Cancer Res. 27:438–446. 2021. View Article : Google Scholar : PubMed/NCBI

Sterling J, Menezes SV, Abbassi RH and Munoz L: Histone lysine demethylases and their functions in cancer. Int J Cancer. Oct 31–2020.(Epub ahead of print). doi: 10.1002/ijc.33375. PubMed/NCBI

Oner E, Kotmakci M, Baird AM, Gray SG, Debelec Butuner B, Bozkurt E, Kantarci AG and Finn SP: Development of EphA2 siRNA-loaded lipid nanoparticles and combination with a small-molecule histone demethylase inhibitor in prostate cancer cells and tumor spheroids. J Nanobiotechnology. 19:712021. View Article : Google Scholar : PubMed/NCBI